Research programme: neurokinin receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: neurokinin receptor antagonists - GlaxoSmithKline

Alternative Names: SB 235375; SB 733210

Latest Information Update: 06 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Acetic acids; Quinolines; Small molecules
  • Mechanism of Action Neurokinin 2 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 22 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory disorders pharmacodynamics section
  • 23 Apr 2002 Preclinical trials in Respiratory tract disorders in USA (unspecified route)
  • 23 Apr 2002 Preclinical trials in Respiratory tract disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top